LIFTUP: Safety and Effectiveness Evaluation of TEOSYAL® TPVM Versus COMPARATOR for the Remodeling of the Lower Face

Sponsor
Teoxane SA (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05986630
Collaborator
(none)
155
1
2
24.8
6.2

Study Details

Study Description

Brief Summary

The clinical study is designed to prospectively evaluate the safety and effectiveness of TEOSYAL® TPVM when compared to COMPARATOR for the remodeling of the lower face

Condition or Disease Intervention/Treatment Phase
  • Device: TEOSYAL® TPVM
  • Device: COMPARATOR
N/A

Detailed Description

This is a prospective, randomized, blinded evaluator, multicenter, clinical study to evaluate safety and effectiveness of TEOSYAL® TPVM versus COMPARATOR for the remodeling of the lower face.

Subject will be enrolled in the study based on evaluation of their chin retrusion severity.

For the purpose of this study, all injections will be done by principal investigators (PIs) with several years of experience in aesthetic treatment.

An external aesthetic and cosmetic surgeon will act as a BE to assess the performance of the treatment and the product based on photographs

Study Design

Study Type:
Interventional
Anticipated Enrollment :
155 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Prospective, Randomized, Blinded Evaluator, Multicenter, Clinical Study to Evaluate Safety and Effectiveness of TEOSYAL® TPVM Versus COMPARATOR for the Remodeling of the Lower Face
Actual Study Start Date :
Apr 6, 2023
Anticipated Primary Completion Date :
Jan 31, 2024
Anticipated Study Completion Date :
Apr 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: TEOSYAL® TPVM

n=116 subjects

Device: TEOSYAL® TPVM
Injection of TEOSYAL® TPVM at Baseline Optional Touch-up treatment at 4 weeks if needed to achieve optimal correction as judged by the PI.

Active Comparator: COMPARATOR

n= 39 subjects

Device: COMPARATOR
Injection of a COMPARATOR at Baseline Optional Touch-up treatment at 4 weeks if needed to achieve optimal correction as judged by the PI.

Outcome Measures

Primary Outcome Measures

  1. Change in TCRS score between Baseline and 8 weeks after last treatment as assessed by the Blinded Evaluator [8 weeks]

    Non-inferiority of TCRS score change from Baseline for subjects treated with TEOSYAL TPVM compared to subjects treated with a COMPARATOR at 8 weeks after last treatment as assessed by the BE. TCRS (Teoxane Chin Retrusion Scale) is a validated 4-point scale assessing chin retrusion severity with 0 being "None/minimal" and 3 being "Severe"

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

Healthy adult subjects over 18 years old seeking correction of their lower face Subject scored grade 2 or 3 on the TCRS Female subjects of childbearing potential must have a negative UPT and practice a reliable method of contraception throughout the study.

Willing to abstain from facial aesthetic procedures/therapies that could interfere with study evaluations Able to follow study instructions and complete all required visits. Having given its signed informed consent

Exclusion Criteria:

Known hypersensitivity or previous allergic reaction to any component of the study devices Known sensitivity to local anesthetics of the amide type, history of multiple severe allergies, or history of anaphylactic shock.

History of active chronic debilitating systemic disease that, in the opinion of the investigator, would make the subject a poor candidate in the study.

Subject exhibits any physical attribute that may prevent assessment or treatment of the lower face as judged by the PI Clinically significant alcohol or drug abuse. Subject has received any investigational product within 90 days prior to Visit 1 or planning to participate in another investigation during the course of the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Canton - Geneva Geneva Switzerland

Sponsors and Collaborators

  • Teoxane SA

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Teoxane SA
ClinicalTrials.gov Identifier:
NCT05986630
Other Study ID Numbers:
  • TEO-TPVM-2101
First Posted:
Aug 14, 2023
Last Update Posted:
Aug 14, 2023
Last Verified:
Aug 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Teoxane SA

Study Results

No Results Posted as of Aug 14, 2023